# Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC

> **NCT07549061** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 19 (estimated)

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** Vebreltinib
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT07549061
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2028-05-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 19 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549061, "Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07549061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*